Wegovy vs Mounjaro: A Decision Guide For SA Patients

The pillar comparison page lays out the facts. This article is for after you have read that and still cannot decide. Both medications work. Both are SAHPRA approved for weight management in SA. Both are weekly injections. So how should you actually pick?

Here is a practical decision framework, organised by the factors that genuinely matter in the choice.

Start With Cost Reality

Cost shapes more decisions in SA healthcare than any clinical factor. Honest pricing comparison:

• Starting month Wegovy: ~R1,873
• Starting month Mounjaro: ~R3,400-R3,600
• Maintenance month Wegovy (2.4 mg): ~R3,746
• Maintenance month Mounjaro (10-15 mg): ~R5,000+

If cost is the deciding factor, Wegovy wins. The gap is significant, particularly during the early titration months when most people are on lower doses. Over a year, the savings compound.

If cost is not the deciding factor, set this aside and look at other factors.

Consider Your Weight Loss Goal

Average trial outcomes:

• Wegovy 2.4 mg: ~15% body weight reduction at 68 weeks
• Mounjaro 15 mg: ~20% body weight reduction at 72 weeks

For most people, 15 percent is a meaningful outcome. For people who need maximum possible weight reduction (very high BMI, significant cardiovascular risk, recommended significant reduction by a specialist), Mounjaro has the average edge.

But: individual variation is wide. Some people respond strongly to Wegovy and get over 20 percent reduction. Some people respond less to Mounjaro and get under 15 percent. The averages are starting points, not guarantees.

Cardiovascular History

If you have established cardiovascular disease (previous heart attack, stroke, peripheral arterial disease, significant coronary disease), Wegovy has a specific advantage. The SELECT trial established a 20 percent reduction in major adverse cardiovascular events. Wegovy is formally approved for this indication.

Mounjaro has emerging cardiovascular data but the SAHPRA cardiovascular indication is not in place yet. For someone with established cardiovascular disease, this is a real point in Wegovy's favour.

Type 2 Diabetes

If you have type 2 diabetes alongside excess weight, Mounjaro has the advantage. It is approved for both indications. Wegovy is not SAHPRA approved for diabetes in SA.

Mounjaro at higher doses produces larger HbA1c reductions than the GLP-1 only medications. For someone with both conditions, Mounjaro is often the more efficient single-medication option.

Adolescent Use

If treatment is for an adolescent aged 12 to 17 with obesity, Wegovy is the only option. Mounjaro is approved for adults only in SA.

Medical History Considerations

Most contraindications apply to both medications (medullary thyroid cancer history, pancreatitis history, pregnancy). A few differences:

• Oral contraception interaction. Mounjaro reduces oral contraceptive absorption (needs backup contraception during start and dose increases). Wegovy does not significantly affect this.
• Mental health history. Both have postmarketing reports of mood changes. Worth honest discussion regardless of which is chosen.
• Severe gastrointestinal tolerance. Some people tolerate one better than the other. There is no way to predict in advance.

The Track Record Factor

Semaglutide (Wegovy active ingredient) has been in use globally since 2017 as Ozempic and since 2021 as Wegovy. Roughly five years of real world use at high prescribing volumes.

Tirzepatide (Mounjaro active ingredient) has been in use globally since 2022 for diabetes and 2023 for weight management. Roughly three years of real world data.

Both are well studied. Semaglutide has a slightly longer track record and more cumulative real world data. For someone who values longer history of use, this slightly favours Wegovy.

Availability And Logistics

Both are available at major SA pharmacies. Both can require occasional stock confirmation. Both are dispensed through the same Online Doctor SA consultation pathway.

No significant difference here at present.

Putting It Together: Decision Patterns

Wegovy is usually the right choice if

• Cost is a significant factor in the decision
• You have established cardiovascular disease and excess weight
• You are an adolescent aged 12 or older
• Your weight loss goal is in the 10 to 15 percent range
• You prefer the longer track record
• You take oral contraceptives and would prefer not to add backup contraception

Mounjaro is usually the right choice if

• You have type 2 diabetes alongside excess weight
• You need maximum possible weight reduction
• You have not responded to GLP-1 only medications previously
• You can afford the higher cost long term

Either is reasonable if

• You are in the middle of the eligibility criteria
• Cost differences are manageable for you
• You have no specific medical reason to favour one
• Your goal is meaningful weight reduction without specifying a target

The Trial Approach

For people who are genuinely undecided, one approach is to start one, see how you respond and tolerate, and switch if needed. The Wegovy starting dose is cheap (~R1,873/month at 0.25 mg) and the titration months give you four months of data before you commit to a maintenance dose. If response is strong, continue. If response or tolerance is inadequate, switch.

This is not the cleanest approach but it is a legitimate one. The treating doctor can guide the switch if it becomes necessary.

The Less Helpful Question

'Which is better?' does not have a clean answer because better depends on what you are optimising for. Cost? Wegovy. Maximum weight loss? Mounjaro. Cardiovascular benefit with existing disease? Wegovy. Combined diabetes and weight? Mounjaro. Adolescent use? Wegovy.

The right question is which fits your situation best. The decision framework above is more useful than the rankings.